[
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04377620",
        "briefTitle": "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation",
        "officialTitle": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19-Associated Acute Respiratory Distress Syndrome (ARDS) Who Are Receiving Mechanical Ventilation (RUXCOVID-DEVENT)"
      },
      "statusModule": {
        "overallStatus": "TERMINATED",
        "startDateStruct": {
          "date": "2020-04-29"
        },
        "completionDateStruct": {
          "date": "2020-05-29"
        }
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": [
          "PHASE3"
        ],
        "primaryPurpose": "TREATMENT",
        "enrollmentInfo": {
          "count": 400
        }
      },
      "eligibilityModule": {
        "sex": "ALL",
        "minimumAge": "12 Years",
        "healthyVolunteers": false
      },
      "conditionsModule": {
        "conditions": [
          {
            "name": "COVID-19",
            "code": "840539006"
          },
          {
            "name": "Acute Respiratory Distress Syndrome",
            "code": "67782005"
          }
        ]
      },
      "armsInterventionsModule": {
        "interventions": [
          {
            "name": "Ruxolitinib",
            "type": "DRUG",
            "description": "Oral ruxolitinib tablets"
          },
          {
            "name": "Placebo",
            "type": "DRUG",
            "description": "Matching placebo tablets"
          }
        ]
      },
      "sponsorCollaboratorsModule": {
        "leadSponsor": {
          "name": "Novartis Pharmaceuticals",
          "class": "INDUSTRY"
        }
      }
    }
  }
]